tbuckley/cabot-search huggingface dataset:
Abstract 19335: Not Your Typical Atrial Flutter
Authors: Matthew D Olson, Selcuk Adabag
Journal: Circulation (2014)

Case: Mr M. presented to the emergency room with two months of progressive shortness of breath and was found to be in atrial flutter with 2:1 conduction at a rate of 140 bpm. His medical history was significant for tobacco use, etoh abuse, and hypertension. Key objective findings included tachycardia, hypoxia an elevated JVP, bibasilar crackles, a summation gallop, and lower extremity edema. His work up included an echocardiogram that illustrated a globally depressed EF (15-20%) and a large “worm like” mass that was free floating and extended into the RV. Management: A heparin drip was already infusing as the initial plan included cardioversion. Since the patient remained hemodynamically stable and there was no evidence of concurrent deep vein thrombosis, a TEE was performed to fully evaluate the mass and to assess the intra-atrial septum for right to left shunting. The TEE with 3D renderings demonstrated a mobile 0.8 x 10 cm mass most consistent with a thrombus that intermittently prolapses through the tricuspid valve into the RV. CT surgery was consulted and discussed the options of thrombolysis vs surgical thrombectomy. Due to the size and apparent dense organization of the thrombus, surgical thrombectomy was performed. When the right atrium was opened after initiation of bypass, there was no visible clot. The main PA was explored and without evidence of the thrombus. As bypass flow decelerated, the clot proceeded into the RA from the IVC cannula. The attached picture illustrates the thrombus removed from the RA and associated echo images. Discussion: Right atrial or ventricular thrombi in transit in hypoxic patients create a challenging clinical dilemma, as distal embolization may be fatal. In this case we chose to surgically remove the thrombus instead of the more commonly employed thrombolytic therapy. The determining factors included clot organization, relative patient stability, and surgical candidacy.
Screening for Acral Lentiginous Melanoma in Dark-Skinned Individuals
Authors: Michael A. Marchetti, Esther Chung, Allan C. Halpern
Journal: JAMA Dermatology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Measuring disease activity and damage in cutaneous lupus erythematosus: reply from authors
Authors: A. Kuhn, V. Ruland, G. Bonsmann
Journal: British Journal of Dermatology (2010)

Journal Article Measuring disease activity and damage in cutaneous lupus erythematosus: reply from authors Get access A. Kuhn, A. Kuhn Department of Dermatology, University of Münster, Münster, Germany E‐mail: kuhnan@uni‐muenster.de Search for other works by this author on: Oxford Academic Google Scholar V. Ruland, V. Ruland Department of Dermatology, University of Münster, Münster, Germany E‐mail: kuhnan@uni‐muenster.de Search for other works by this author on: Oxford Academic Google Scholar G. Bonsmann G. Bonsmann Department of Dermatology, University of Münster, Münster, Germany E‐mail: kuhnan@uni‐muenster.de Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 164, Issue 1, 1 January 2011, Pages 222–224, https://doi.org/10.1111/j.1365-2133.2010.10073.x Published: 01 January 2011
Abstract 1908: The Wnt-target Prox1 promotes colorectal cancer stem cell survival to fuel tumor growth
Authors: Zoltan Wiener, Ville Hyvönen, Jenny Högström, Tanja Holopainen, Arja Band, Pauliina Kallio, Olli Dufva, Caj Haglund, Olli Kruuna, Guillermo Oliver, Yinon Ben-Neriah, Kari Alitalo
Journal: Cancer Research (2014)

Abstract Colorectal cancer (CRC) is one of the leading causes of cancer mortality in the Western countries. In most of the CRC patients, an initial mutation occurs in the APC or CTNNB1 genes, leading to the ligand-independent activation of the canonical Wnt pathway. Besides having a central role in the development of CRC, the Wnt pathway plays a critical role also in the maintenance of the normal intestine. Attempts at therapeutic inhibition of this pathway could thus lead to serious side effects in CRC patients. We have previously shown that the Prox1 transcription factor is induced in the intestinal epithelium by mutations activating the Wnt pathway and it critically contributes to CRC progression via an unknown mechanism. Here we provide evidence that Prox1 expression is induced in the Lgr5+ adenoma stem cells early after Apc deletion. Our in vivo models and ex vivo organoid experiments suggest that Prox1 silencing or deletion restricts the expansion of the Lgr5+ adenoma stem cell population both in humans and in mice. Interestingly, silencing the phospholipid binding protein Annexin A1 (Anxa1), a gene suppressed by Prox1, is responsible for several of the effects of Prox1 on adenoma cells, such as the re-organization of the actin cytoskeleton, enhanced stem cell activity and tumor growth. Furthermore, Prox1 deletion abnormally increases the mTORC1 pathway activity, which results in decreased survival of the adenoma stem cells. Since Prox1 is expressed at low level only in rare neuroendocrine cells and in some Paneth cells in the wild type intestinal epithelium, furthermore, its genetic deletion in the adult gut does not lead to obvious phenotypes, Prox1 may serve as an attractive therapeutic target for restricting the progression of early intestinal adenomas. Citation Format: Zoltan Wiener, Ville Hyvönen, Jenny Högström, Tanja Holopainen, Arja Band, Pauliina Kallio, Olli Dufva, Caj Haglund, Olli Kruuna, Guillermo Oliver, Yinon Ben-Neriah, Kari Alitalo. The Wnt-target Prox1 promotes colorectal cancer stem cell survival to fuel tumor growth. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1908. doi:10.1158/1538-7445.AM2014-1908
Advances in endophenotyping schizophrenia
Authors: DAVID L. BRAFF, TIFFANY A. GREENWOOD, NEAL R. SWERDLOW, GREGORY A. LIGHT, NICHOLAS J. SCHORK
Journal: World Psychiatry (2008)

The search for the genetic architecture of schizophrenia has employed multiple, often converging strategies. One such strategy entails the use of tracing the heritability and neurobiology of endophenotypes. Endophenotypes are quantifiable traits not visible to the eye, which are thought to reflect an intermediate place on the path from genes to disorder. Endophenotype abnormalities in domains such as neurophysiology or neurocognition occur in schizophrenia patients as well as their clinically "unaffected" relatives, and reflect polymorphisms in the DNA of schizophrenia spectrum subjects which create vulnerability to developing schizophrenia. By identifying the single nucleotide polymorphisms (SNPs) associated with endophenotypes in schizophrenia, psychiatric neuroscientists can select new strong inference based molecular targets for the treatment of schizophrenia.
Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro
Authors: M. Elishmereni, H. T. Alenius, P. Bradding, S. Mizrahi, A. Shikotra, Y. Minai-Fleminger, D. Mankuta, R. Eliashar, G. Zabucchi, F. Levi-Schaffer
Journal: Allergy (2010)

To cite this article: Elishmereni M, Alenius HT, Bradding P, Mizrahi S, Shikotra A, Minai-Fleminger Y, Mankuta D, Eliashar R, Zabucchi G, Levi-Schaffer F. Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro. Allergy 2011; 66: 376–385. Abstract Background: Mast cells (MCs) and eosinophils (Eos) are the key effector cells of the allergic reaction. Although classically associated with different stages of the response, the cells co-exist in the inflamed tissue in the late and chronic phases in high numbers and are likely to cross-talk. While some mediators of MCs are known to affect Eos biology and vice versa, paracrine and physical interplay between the two cells has not been described yet. We aimed to investigate whether intercellular MC–Eos communication could take place in the allergic response and exert functional bidirectional changes on the cells. Methods: Tissue sections from various allergic disorders were specifically stained for both cells. Human cord blood-derived MCs and peripheral blood Eos, co-cultured under different conditions, were studied by advanced microscopy and flow cytometry. Results: Several co-localized MC–Eos pairs were detected in human nasal polyps and asthmatic bronchi, as well in mouse atopic dermatitis. In vitro, MCs and Eos formed stable conjugates at high rates, with clear membrane contact. In the presence of MCs, Eos were significantly more viable under several co-culture conditions and at both IgE-activated and steroid-inhibited settings. MC regulation of Eos survival required communication through soluble mediators but was even more dependent on physical cell–cell contact. Conclusions: Our findings provide the first evidence for a complex network of paracrine and membrane interactions between MCs and Eos. The prosurvival phenotype induced by this MC–Eos interplay may be critical for sustaining chronic allergic inflammation.
Infantile haemangioma: New aspects on the pathogenesis of the most common skin tumour in children
Authors: P.H. Hoeger
Journal: British Journal of Dermatology (2011)

Journal Article Infantile haemangioma: New aspects on the pathogenesis of the most common skin tumour in children Get access P.H. Hoeger P.H. Hoeger Department of Paediatric Dermatology, Catholic Children's Hospital Wilhelmstift, 22149 Hamburg, Germany E‐mail: hoeger@kkh‐wilhelmstift.de Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 164, Issue 2, 1 February 2011, Pages 234–235, https://doi.org/10.1111/j.1365-2133.2011.10204.x Published: 01 February 2011
Amyloid-DNA Composites of Bacterial Biofilms Stimulate Autoimmunity
Authors: Paul M. Gallo, Glenn J. Rapsinski, R. Paul Wilson, Gertrude O. Oppong, Uma Sriram, Mark Goulian, Bettina Buttaro, Roberto Caricchio, Stefania Gallucci, Çagla Tükel
Journal: Immunity (2015)
Abstract P107: Are Sleep Disturbances Associated with the Development of Gestational Diabetes? A Systematic Review and Meta-analysis.
Authors: Michelle A Miller, Ponnusamy Saravanan, Manu Vatish, Francesco P Cappuccio
Journal: Circulation (2014)

Introduction and objectives: Physiological and hormonal changes occurring in pregnancy increase the risk of sleep disordered breathing (SDB), which, along with short sleep (SS) duration, may be associated with an increased risk of gestational diabetes mellitus (GDM). Exposure to GDM in the mother increases her lifetime risk of type-2 diabetes (T2D) as well as the risk of obesity, metabolic syndrome and, in later life, T2D of her children. The aim of this study was to systematically review the collective published evidence of associations between snoring/sleep-disordered breathing or sleep duration and increased risk of GDM. Hypothesis: We assessed the hypotheses that sleep disturbances, and/or short sleep during pregnancy may be associated with an increased risk of GDM. Materials and Methods: We performed systematic searches using MEDLINE, EMBASE, the Cochrane library and PsycINFO to assess the effect of snoring/sleep disordered breathing (SDB) or short sleep (SS) on the development of gestational diabetes (GDM) and impaired glucose tolerance in pregnancy. Prospective studies with measures of sleep disturbances at baseline and outcome measures of GDM or levels of glucose 1hr post GCT were included in a meta-analysis. We extracted odds ratios (OR) or relative risks (RR) and 95% confidence intervals (CI) and pooled them using a random effect model. Results: Overall, 7 studies met the inclusion criteria. They included 4,292 participants with 311 cases of GDM. In the pooled analysis, snoring/SDB and SS were both associated with a greater risk of GDM (RR: 2·27; 95% CI 1·65 to 3·12; P &lt; 0· 00001) and (3·19 [1·56 to 6·54]; P &lt; 0·002), respectively. There was no evidence of heterogeneity but there was evidence of publication bias and not all studies adjusted for obesity. Sensitivity analyses did not influence the pooled risk estimates. Conclusions: In conclusion, sleep disturbances may represent a risk factor for the development of GDM. Further studies are required to address the issues of publication bias and potential confounding, and to extend these observations to high-risk groups like women of ethnic minority groups whose risk of GDM is the greatest. Prevention, detection and treatment strategies need to be explored.
Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study
Authors: A.B. Olesen, C. Svaerke, D.K. Farkas, H.T. Sørensen
Journal: British Journal of Dermatology (2010)

Background Earlier studies reported an increased cancer risk among patients with systemic sclerosis. Study size limitations and paucity of population‐based study designs may have resulted in imprecise risk estimates. Objectives To assess cancer risk among patients with systemic sclerosis in a nationwide follow‐up study. Methods Patients with a first diagnosis of systemic sclerosis from 1977 to 2006 were identified from the nationwide Danish National Registry of Patients (DNRP), whose records encompass all hospitalizations and outpatient visits. Patients' DNRP records were linked to the Danish Cancer Registry. We compared their cancer incidence with that expected from cancer incidence in the general population, calculating standardized incidence ratios (SIRs) and 95% confidence intervals (CIs). Results Two thousand and forty patients with systemic sclerosis were identified and followed for 16 003 person‐years, with a median follow‐up time of 6·4 years (interquartile range 2·2–11·5). Among these patients, 222 cases of cancer were identified. The overall SIR for cancer was 1·5 (95% CI 1·3–1·7), with a gender‐specific SIR of 2·2 (95% CI 1·7–2·8) for men and 1·3 (95% CI 1·1–1·6) for women. The most frequent cancers were smoking‐ and alcohol‐related cancers including lung cancer (SIR = 1·6, 95% CI 1·2–2·0), haematological cancers (SIR = 2·5, 95% CI 1·5–4·0) and immune‐related cancers (SIR = 1·4, 95% CI 1·0–1·9). Conclusions Systemic sclerosis is a risk factor for cancer, particularly smoking‐ and alcohol‐related cancers. Men with systemic sclerosis generally are at higher cancer risk than women. Both primary and secondary cancer preventive measures are needed in the care of patients with systemic sclerosis.
Abstract 4218: Combined effect of COX2 genotype, ER status, body constitution, and treatment on risk of early events in breast cancer patients
Authors: Andrea Markkula, Maria Simonsson, Christian Ingvar, Carsten Rose, Helena Jernström
Journal: Cancer Research (2014)

Abstract Aim: The aim of the present study was to investigate the impact of the COX2 rs5277 polymorphism on early events and treatment response in relation to tumor ER-status and to determine whether any effect is modified by body constitution. Background: The synonymous COX2 rs5277 polymorphism (306G&amp;gt;C, V102V) has been directly linked to several cancers associated with inflammation. Breast cancer patients with tumors expressing COX-2 have a shorter disease-free survival. It is currently unclear whether the rs5277 genotype is correlated with tumor COX-2 expression. Tumor COX-2 expression may have contrasting effects on breast cancer tumors depending on the tumor's estrogen receptor (ER) status. It has been associated with increased estrogen levels in ER-positive tumors and Akt-pathway activation in ER-negative tumors. Methods: The present study is based on data collected from 634 patients initiating treatment between October 2002 and October 2008. Risk of early events was assessed for 570 rs5277-genotyped patients. Body measurements and questionnaires were obtained at the pre-operative visit. Clinical data, patient-, and tumor-characteristics were obtained from questionnaires, patients' charts, population registries, and pathology reports. Results: Among all patients, 70.1% were GG-carriers, 27.5% were GC-carriers, and 2.4% were CC-carriers. Median follow-up was 5.1 years. Median age was 59.6 years (range 25-99 years). No association was seen between the G/G genotype and risk of early events in patients with ER-positive tumors, but this genotype conferred an over 4-fold increased risk in patients with ER-negative tumors (Pinteraction=0.015). G/G-carriers with a larger breast volume who had received chemotherapy had a 9-fold risk of early events irrespective of ER-status. C-allele carriers with ER-positive tumors who had a larger breast volume and had received endocrine-therapy had a 2-fold increased risk of early events. Conclusion: COX2 genotype, body constitution, and ER-status had a combined effect on the risk of early events and treatment response. The high risk for early events in certain subgroups of patients suggests that COX2 genotype in combination with body measurements may provide a tool for identifying patients in need of more personalized treatment. Citation Format: Andrea Markkula, Maria Simonsson, Christian Ingvar, Carsten Rose, Helena Jernström. Combined effect of COX2 genotype, ER status, body constitution, and treatment on risk of early events in breast cancer patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4218. doi:10.1158/1538-7445.AM2014-4218
Medical Student Exposure to Drug Company Interactions—Reply
Authors: Frederick S. Sierles
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3537: Oral Contraceptives Cause Major C-reactive Protein Rises in the Female General Population
Authors: Ernst Rietzschel, Marc De Buyzere, Dirk De Baquer, Michel Langlois, Sofie Bekaert, Patrick Segers, Piet Van Damme, Pascal Verdonck, Guy De Backer, Thierry C Gillebert, Asklepios investigators
Journal: Circulation (2007)

Purpose: High-sensitive C-reactive protein (hs-CRP) is a marker of inflammation, identifying subjects at increased cardiovascular risk. Hormonal therapy with estrogen (E) alone or combined with pro...
High prevalence of FEV1 decline without diagnose
Authors: Sergey Fedosenko, Evgeny Kulikov, Olga Kobyakova, Margarita Muzykina, Ivan Deev, Elena Starovoytova, Natalya Kirillova, Natalia Kosova, Vadim Boykov, Olesya Laricheva, Yulia Chatorova, Sofya Mazeina, Alisa Almikeeva
Journal: European Respiratory Journal (2013)

Background: Reduced FEV1 is known to predict and associated with different diseases and increased lung cancer risk and other. But the data of FEV1 decline prevalence in different regions are limited.  Objective: To assess the prevalence of FEV1 decline and risk factors at the population of visitors of Health Promotion Centers in Tomsk region of Russia.  Materials and Methods: In Russia at 2006 launched national project Health, whose goal is to promote public health. Medical history, information about risk factors, clinical and spirometry (ATS) were collected from 2500 subjects attending a Health Promotion Centers in Tomsk region of Russia from 2010 to 2011. Predicted spirometry values were calculated from NHANES III dataset.  Results and discussion: A total of 2500 individuals underwent spirometry. Using the pre bronchodilator criteria, 643 (25%) patients had airflow obstruction. Of them 297 (46%) patients had FEV1 - 70-80%, 177 (27%) patients had FEV1 - 60-70% and 169 (26%) subjects had FEV1 -  80% (25,75±5,58 vs 27,17±6,60 vs 27,43±5,66; p  Conclusions: Of 2500 individuals attending a Health Promotion Centers in Tomsk region of Russia 25% had airflow obstruction and only in 16% of cases airflow obstruction was previously diagnosed and indicated in medical records. Smoking was strongly associated with airflow obstruction.